Johnson & Johnson (NYSE:JNJ) has agreed to acquire Momenta Pharmaceuticals (NASDAQ:MNTA) for $52.50 per share in cash for a total of $6.5B.
The transaction should close in H2.
Momenta develops therapies for rare immune-mediated disorders leveraging its Fc Multimerization Platform. Lead candidate is nipocalimab, in Phase 3 development for warm autoimmune hemolytic anemia and Phase 2 for hemolytic disease of fetus and newborn and myasthenia gravis.
